Literature DB >> 17918924

Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.

Qian Liu1, Brian Masek, Karl Smith, Julian Smith.   

Abstract

Here we describe a computer-assisted de novo drug design method, EAISFD, which combines the de novo design engine EA-Inventor with a scoring function featuring the molecular docking program Surflex-Dock. This method employs tagged fragments, which are preserved substructures in EA-Inventor used for base fragment matching in Surflex-Dock, for constructing ligand structures under specific binding motifs. In addition, a target score mechanism is adopted that allows EAISFD to deliver a diverse set of desired structures. This method can be used to design novel ligand scaffolds (lead generation) or to optimize attachments on a fixed scaffold (lead optimization). EAISFD has successfully suggested many known inhibitor scaffolds as well as a number of new scaffold types when applied to p38 MAP kinase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918924     DOI: 10.1021/jm070750k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Evaluating the therapeutic potential of a non-natural nucleotide that inhibits human ribonucleotide reductase.

Authors:  Md Faiz Ahmad; Qun Wan; Shalini Jha; Edward Motea; Anthony Berdis; Chris Dealwis
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

2.  Automated design of ligands to polypharmacological profiles.

Authors:  Jérémy Besnard; Gian Filippo Ruda; Vincent Setola; Keren Abecassis; Ramona M Rodriguiz; Xi-Ping Huang; Suzanne Norval; Maria F Sassano; Antony I Shin; Lauren A Webster; Frederick R C Simeons; Laste Stojanovski; Annik Prat; Nabil G Seidah; Daniel B Constam; G Richard Bickerton; Kevin D Read; William C Wetsel; Ian H Gilbert; Bryan L Roth; Andrew L Hopkins
Journal:  Nature       Date:  2012-12-13       Impact factor: 49.962

3.  Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization.

Authors:  Rajnish Kumar; Bengt Långström; Taher Darreh-Shori
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

4.  Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.

Authors:  Bo-Han Su; Yi-Syuan Huang; Chia-Yun Chang; Yi-Shu Tu; Yufeng J Tseng
Journal:  Molecules       Date:  2013-10-31       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.